STOCK TITAN
  1. Home
  2. Sec-filings
  3. DGX
  4. [8-K] QUEST DIAGNOSTICS INC Reports Material Event

Quest Diagnostics (NYSE: DGX) boosts 2026 revenue and EPS outlook after Q2

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Quest Diagnostics reported strong second-quarter 2026 results. Net revenues were $3.04 billion, up 10.2% year over year, including 10.0% organic revenue growth and a 13.1% increase in requisition volume, while revenue per requisition declined.

Reported diluted EPS rose 15.0% to $2.84, and adjusted diluted EPS increased 19.1% to $3.12. For the first six months of 2026, net revenues were $5,938 million and diluted EPS was $5.08. Operating cash flow reached $875 million, funding $252 million of capital expenditures and $100 million of share repurchases, as cash and equivalents increased to $626 million.

The company raised full‑year 2026 guidance, now expecting net revenues of $11.95–$12.05 billion, reported diluted EPS of $9.97–$10.17, and adjusted diluted EPS of $11.05–$11.25. Expected cash from operations was increased to approximately $1.80 billion, with capital spending still projected at about $550 million.

Positive

  • Second-quarter 2026 net revenues rose 10.2% to $3.04 billion, supported by a 13.1% increase in requisition volume and 10.0% organic revenue growth.
  • Reported diluted EPS increased 15.0% to $2.84, while adjusted diluted EPS grew 19.1% to $3.12 year over year.
  • Full-year 2026 net revenue guidance was raised to $11.95–$12.05 billion, and adjusted diluted EPS guidance to $11.05–$11.25.
  • First-half 2026 operating cash flow reached $875 million, exceeding capital expenditures and funding $100 million of share repurchases, while cash rose to $626 million.

Negative

  • None.

Filing Explained

By June 30, 2026, debt had a lower current portion and higher long-term portion, while $1.3 billion of repurchase authorization remained as capacity.

This Form 8-K reports the company’s completed second-quarter results for the period ended June 30, 2026, and states that 0.5 million common shares were repurchased for $100 million during the first six months.

That repurchase is an executed issuer transaction affecting treasury stock; the separate $1.3 billion remaining authorization is available capacity, not a disclosed commitment to buy that amount.

The filing defines reported measures as GAAP and adjusted measures as non-GAAP measures excluding listed special items such as restructuring, amortization, and certain investment gains or losses.

The $1.3 billion remaining repurchase authorization is the specific line item to monitor because this filing gives no future purchase schedule.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q2 2026 Net Revenues $3.04 billion Second quarter 2026 net revenues, up 10.2% from 2025
Q2 2026 Diluted EPS $2.84 Second quarter 2026 reported diluted EPS, up 15.0% year over year
Q2 2026 Adjusted Diluted EPS $3.12 Second quarter 2026 adjusted diluted EPS, up 19.1% from 2025
First-Half 2026 Net Revenues $5,938 million Net revenues for the six months ended June 30, 2026, up 9.7% from 2025
First-Half 2026 Operating Cash Flow $875 million Net cash provided by operating activities for the six months ended June 30, 2026
2026 Net Revenue Guidance Low End $11.95 billion Updated 2026 net revenue guidance low end; high end $12.05 billion
2026 Adjusted Diluted EPS Guidance Low End $11.05 Updated 2026 adjusted diluted EPS guidance low end; high end $11.25
2026 Share Repurchases $100 million Cash spent to repurchase 0.5 million shares in the six months ended June 30, 2026
Adjusted diluted EPS financial
"adjusted diluted EPS of $3.12, up 19.1% from 2025"
Adjusted diluted EPS is a company’s profit per share after adding back or removing one-time items (like restructuring costs or gains) and dividing by the number of shares including potential shares from options and convertible securities. Investors use it as a cleaner view of ongoing earnings—like looking at a car’s regular fuel efficiency rather than a trip boosted by downhill coasting—to judge underlying performance and compare companies without temporary distortions.
Requisition volume financial
"Requisition volume | | | | | 13.1 | %"
The total number or quantity of purchase requests or orders submitted to a supplier, vendor, laboratory, or internal procurement system over a given period. It measures how many units, tests, services, or items have been formally requested, and acts like a shopping list that signals upcoming demand, production needs, inventory changes and the near-term sales pipeline that investors watch as an indicator of future revenue and operational pressure.
Contingent consideration accrual financial
"change in the fair value of the contingent consideration accrual"
Equity method investees financial
"Equity in earnings of equity method investees, net of taxes"
Equity method investees are companies in which an investor owns a substantial minority stake and can influence decisions but does not control them, typically through holding around 20–50% of voting shares. The investor records its share of the investee’s profits or losses on its own income statement and adjusts the carrying value of the investment, similar to reporting your share of profits from a jointly owned shop. For investors, these holdings matter because they affect reported earnings, balance-sheet exposure, and the firm’s economic risk without full consolidation of the investee’s assets and liabilities.
Excess tax benefits financial
"excess tax benefits ("ETB") associated with stock-based compensation"
Noncontrolling interests financial
"Less: Net income attributable to noncontrolling interests"
The portion of a subsidiary’s equity and profits that belongs to outside owners rather than the parent company; when a parent reports consolidated results it includes the whole subsidiary but shows the noncontrolling slice separately. Think of a company’s subsidiary as a pie where the parent owns most slices but some are held by other investors — noncontrolling interests tell you how much of the pie and its future earnings don’t belong to the parent, which affects how much profit and net assets are truly attributable to the parent’s shareholders.
Net revenues $3.04 billion up 10.2% from 2025
Diluted EPS $2.84 up 15.0% from 2025
Adjusted diluted EPS $3.12 up 19.1% from 2025
2026 net revenue guidance $11.95–$12.05 billion raised from $11.78–$11.90 billion
2026 adjusted diluted EPS guidance $11.05–$11.25 raised from $10.63–$10.83
Guidance

For 2026, the company expects net revenues of $11.95–$12.05 billion, reported diluted EPS of $9.97–$10.17, and adjusted diluted EPS of $11.05–$11.25.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

How did Quest Diagnostics (DGX) perform in Q2 2026?
Quest Diagnostics reported Q2 2026 net revenues of $3.04 billion, up 10.2% year over year. Reported diluted EPS was $2.84 and adjusted diluted EPS was $3.12, increases of 15.0% and 19.1%, respectively, versus 2025.

What revenue drivers did Quest Diagnostics (DGX) highlight for Q2 2026?
The company cited 10.0% organic revenue growth and a 13.1% increase in requisition volume in Q2 2026. Revenue per requisition declined 2.8%, but overall Diagnostic Information Services revenues still increased 10.3% versus Q2 2025.

What is Quest Diagnostics’ (DGX) updated full-year 2026 guidance?
For 2026, Quest Diagnostics now expects net revenues of $11.95–$12.05 billion, reported diluted EPS of $9.97–$10.17, and adjusted diluted EPS of $11.05–$11.25. Net revenue growth guidance is 8.3–9.2% year over year.

How did Quest Diagnostics’ (DGX) cash flow and investments look for the first half of 2026?
For the first six months of 2026, Quest Diagnostics generated $875 million of operating cash flow and spent $252 million on capital expenditures. Net cash used in investing was $286 million, and cash and equivalents increased to $626 million at June 30, 2026.

Did Quest Diagnostics (DGX) repurchase shares in 2026 so far?
Yes. In the first half of 2026, Quest Diagnostics repurchased 0.5 million shares of its common stock for $100 million. As of June 30, 2026, $1.3 billion remained available under the company’s share repurchase authorization.

What non-GAAP measures does Quest Diagnostics (DGX) use in its 2026 results?
Quest Diagnostics reports adjusted operating income, adjusted net income, and adjusted diluted EPS, excluding items such as restructuring and integration charges, amortization expense, gains and losses on investments, excess tax benefits, and other specified items.
0001022079false00010220792026-07-232026-07-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): July 23, 2026
Quest Diagnostics Incorporated
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or other jurisdiction of incorporation)
001-1221516-1387862
(Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive
Secaucus, NJ07094
(Address of principal executive offices)(Zip Code)
(973)520-2700
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 Par ValueDGXNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02. Results of Operations and Financial Condition

On July 23, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
    
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1
Press release of Quest Diagnostics Incorporated dated July 23, 2026, announcing, among other things, its results for the quarter ended June 30, 2026.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.


Signature
    
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

July 23, 2026

QUEST DIAGNOSTICS INCORPORATED
By:/s/ Sean D. Mersten
Sean D. Mersten
Vice President and Corporate Secretary






Exhibit 99.1


Quest Diagnostics Reports Second Quarter 2026 Financial Results;
Raises Revenue and EPS Guidance for Full Year 2026
    
•Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth
•Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted diluted EPS of $3.12, up 19.1% from 2025
•Full year 2026 revenues now expected to be between $11.95 billion and $12.05 billion
•Full year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25

SECAUCUS, N.J., July 23, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.

“Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health,” said Jim Davis, Chairman, CEO and President. “Revenues increased by over 10%, almost all from organic revenue growth across our physician, hospital and consumer channels, and adjusted diluted EPS grew over 19%. With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance.”

Recent Highlights:

Serving Customers and Delivering Innovations
•Continued to advance our Co-Lab Solutions implementation and joint venture laboratory with Corewell Health in Michigan and developed new capabilities in kidney care through our collaboration with Fresenius Medical Care in the United States.
•Generated robust revenue growth through questhealth.com and our consumer, wearable and wellness partners.
•Grew revenues by double-digits in several areas of Advanced Diagnostics, including Quest AD-Detect® blood tests for Alzheimer’s disease and advanced cardiometabolic and endocrine tests, including liver fibrosis testing.
•Granted New York State approval for our Haystack MRD® test and became the largest reference lab to utilize Flatiron Health's OncoEMR® Molecular Profiling Integration (MPI) platform for select cancer tests, including Haystack MRD, starting with a pilot with American Oncology Network (AON).

Driving Operational Excellence
•In the lab, extended automation solutions to improve quality and productivity in cervical cancer screening and front-end specimen processing to additional labs.
•Outside the lab, launched IntelliDraw™ to guide clinical staff of our physician customers through specimen collection, to enhance quality and the service experience.
1



Three Months Ended June 30,Six Months Ended June 30,
20262025Change20262025Change
(dollars in millions, except per share data)
Reported:
Net revenues$3,043 $2,761 10.2 %$5,938 $5,413 9.7 %
Diagnostic Information Services revenues$2,978 $2,699 10.3 %$5,810 $5,288 9.9 %
Revenue per requisition(2.8)%(2.1)%
Requisition volume13.1 %12.0 %
  Organic requisition volume13.0 %11.9 %
Operating income (a)$459 $438 4.6 %$858 $784 9.4 %
Operating income as a percentage of net revenues (a)15.1 %15.9 %(0.8)%14.4 %14.5 %(0.1)%
Net income attributable to Quest Diagnostics (a)$320 $282 13.4 %$572 $502 13.9 %
Diluted EPS (a)$2.84 $2.47 15.0 %$5.08 $4.41 15.2 %
Cash provided by operations $597 $544 9.7 %$875 $858 1.9 %
Capital expenditures$138 $108 27.0 %$252 $225 12.1 %
Adjusted (a):
Operating income$502 $466 7.8 %$949 $872 8.8 %
Operating income as a percentage of net revenues16.5 %16.9 %(0.4)%16.0 %16.1 %(0.1)%
Net income attributable to Quest Diagnostics$350 $298 17.3 %$631 $549 14.9 %
Diluted EPS$3.12 $2.62 19.1 %$5.62 $4.83 16.4 %
(a)For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

Updated Guidance for Full Year 2026

The company updates its full year 2026 guidance as follows:

Updated GuidancePrior Guidance
LowHighLowHigh
Net revenues$11.95 billion$12.05 billion$11.78 billion$11.90 billion
Net revenues increase8.3%9.2%6.8%7.8%
Reported diluted EPS$9.97$10.17$9.58$9.78
Adjusted diluted EPS$11.05$11.25$10.63$10.83
Cash provided by operationsApproximately $1.80 billionApproximately $1.75 billion
Capital expenditures  Approximately $550 millionApproximately $550 million

Based on the favorable resolution of various tax contingencies in the second quarter, the full year adjusted effective tax rate is expected to be consistent with 2025.

Note on Non-GAAP Financial Measures

As used in this press release the term “reported” refers to measures under accounting principles generally accepted in the United States (“GAAP”). The term “adjusted” refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.

2



Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on July 23, 2026 until midnight Eastern Time on August 6, 2026, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About Quest Diagnostics

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com.

Forward Looking Statements

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

For further information: Wendy Bost, Quest Diagnostics (Media): 973-520-2800, Daniel Haemmerle, Quest Diagnostics (Investors): 973-520-2900

This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.


ADDITIONAL TABLES FOLLOW
3


Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations
For the Three and Six Months Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Net revenues $3,043 $2,761 $5,938 $5,413 
Operating costs and expenses and other operating income:   
Cost of services2,016 1,818 3,969 3,607 
Selling, general and administrative 529 486 1,033 962 
Amortization of intangible assets38 39 75 78 
Other operating expense (income), net1 (20)3 (18)
Total operating costs and expenses, net 2,584 2,323 5,080 4,629 
Operating income459 438 858 784 
Other income (expense):    
Interest expense, net(63)(67)(126)(134)
Other income, net16 13 14 10 
Total non-operating expense, net(47)(54)(112)(124)
Income before income taxes and equity in earnings of equity method investees412 384 746 660 
Income tax expense(88)(97)(162)(156)
Equity in earnings of equity method investees, net of taxes10 9 14 27 
Net income334 296 598 531 
Less: Net income attributable to noncontrolling interests14 14 26 29 
Net income attributable to Quest Diagnostics$320 $282 $572 $502 
Earnings per share attributable to Quest Diagnostics’ common stockholders:
Basic$2.88 $2.51 $5.15 $4.48 
Diluted$2.84 $2.47 $5.08 $4.41 
Weighted average common shares outstanding:
Basic111 112 110 112 
Diluted112 113 112 113 

4


Quest Diagnostics Incorporated and Subsidiaries
Consolidated Balance Sheets
June 30, 2026 and December 31, 2025
(in millions, except per share data)
(unaudited)
June 30,
2026		December 31,
2025
Assets
Current assets:
Cash and cash equivalents$626 $420 
Accounts receivable, net1,666 1,408 
Inventories233 189 
Prepaid expenses and other current assets319 361 
Total current assets2,844 2,378 
Property, plant and equipment, net2,219 2,203 
Operating lease right-of-use assets678 657 
Goodwill9,112 8,945 
Intangible assets, net1,672 1,636 
Investments in equity method investees137 136 
Other assets277 270 
Total assets$16,939 $16,225 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses$1,598 $1,600 
Current portion of long-term debt10 504 
Current portion of long-term operating lease liabilities180 174 
Total current liabilities1,788 2,278 
Long-term debt5,632 5,167 
Long-term operating lease liabilities561 537 
Other liabilities1,059 957 
Redeemable noncontrolling interest80 80 
Stockholders’ equity:
Quest Diagnostics stockholders’ equity:
Common stock, par value $0.01 per share; 600 shares authorized as of both June 30, 2026 and December 31, 2025; 162 shares issued as of both June 30, 2026 and December 31, 2025
2 2 
Additional paid-in capital2,374 2,381 
Retained earnings10,374 9,994 
Accumulated other comprehensive loss(62)(27)
Treasury stock, at cost; 52 shares as of both June 30, 2026 and December 31, 2025
(5,172)(5,180)
Total Quest Diagnostics stockholders’ equity7,516 7,170 
Noncontrolling interests303 36 
Total stockholders’ equity7,819 7,206 
Total liabilities and stockholders’ equity$16,939 $16,225 

5


Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Cash Flows
For the Six Months Ended June 30, 2026 and 2025
(in millions)
(unaudited)
Six Months Ended June 30,
20262025
Cash flows from operating activities:
Net income$598 $531 
Adjustments to reconcile net income to net cash provided by operating activities:  
Depreciation and amortization293 283 
Provision for credit losses3 2 
Deferred income tax expense46 8 
Stock-based compensation expense43 43 
Other, net14 26 
Changes in operating assets and liabilities: 
Accounts receivable(259)(115)
Accounts payable and accrued expenses130 (11)
Income taxes payable4 9 
Other assets and liabilities, net3 82 
Net cash provided by operating activities875 858 
Cash flows from investing activities:
Business acquisitions, net of cash acquired(38)(17)
Capital expenditures(252)(225)
Other investing activities, net4 3 
Net cash used in investing activities(286)(239)
Cash flows from financing activities:
Proceeds from borrowings494 400 
Repayments of debt(501)(1,001)
Purchases of treasury stock(102)— 
Exercise of stock options81 42 
Employee payroll tax withholdings on stock issued under stock-based compensation plans(38)(42)
Dividends paid(184)(174)
Distributions to noncontrolling interest partners(22)(29)
Other financing activities, net(109)(50)
Net cash used in financing activities(381)(854)
Effect of exchange rate changes on cash and cash equivalents and restricted cash(2)5 
Net change in cash and cash equivalents and restricted cash206 (230)
Cash and cash equivalents and restricted cash, beginning of period420 549 
Cash and cash equivalents and restricted cash, end of period$626 $319 
Cash paid during the period for:
Interest$129 $145 
Income taxes$104 $110 




6







Notes to Financial Tables

1)The computation of basic and diluted earnings per common share is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
(in millions, except per share data)
Amounts attributable to Quest Diagnostics' common stockholders:
Net income attributable to Quest Diagnostics$320 $282 $572 $502 
Less: earnings allocated to participating securities1 1 2 2 
Earnings available to Quest Diagnostics' common stockholders - basic and diluted
$319 $281 $570 $500 
Weighted average common shares outstanding - basic111 112 110 112 
Effect of dilutive securities:
Stock options and performance share units1 1 2 1 
Weighted average common shares outstanding - diluted112 113 112 113 
Earnings per share attributable to Quest Diagnostics' common stockholders:
Basic$2.88 $2.51 $5.15 $4.48 
Diluted$2.84 $2.47 $5.08 $4.41 

2)The following tables reconcile reported GAAP results to non-GAAP adjusted results:
Three Months Ended June 30, 2026
(dollars in millions, except per share data)
Operating incomeOperating income as a percentage of net revenuesIncome tax expense (e)Equity in earnings of equity method investees, net of taxesNet income attributable to Quest DiagnosticsDiluted EPS
As reported$459 15.1 %$(88)$10 $320 $2.84 
Restructuring and integration charges (a)4 0.2 (1)— 3 0.04 
Other charges (b)1 — 1 — 2 0.02 
Gains and losses on investments (c)— — — (1)(1)(0.01)
Amortization expense38 1.2 (10)— 28 0.25 
ETB— — (2)— (2)(0.02)
As adjusted$502 16.5 %$(100)$9 $350 $3.12 

7


Six Months Ended June 30, 2026
(dollars in millions, except per share data)
Operating incomeOperating income as a percentage of net revenuesIncome tax expense (e)Equity in earnings of equity method investees, net of taxesNet income attributable to Quest DiagnosticsDiluted EPS
As reported$858 14.4 %$(162)$14 $572 $5.08 
Restructuring and integration charges (a)11 0.2 (3)— 8 0.08 
Other charges (b)5 0.1 — — 5 0.05 
Gains and losses on investments (c)— — (2)6 4 0.04 
Amortization expense75 1.3 (19)— 56 0.50 
ETB— — (14)— (14)(0.13)
As adjusted$949 16.0 %$(200)$20 $631 $5.62 
Three Months Ended June 30, 2025
(dollars in millions, except per share data)
Operating incomeOperating income as a percentage of net revenuesIncome tax expense (e)Equity in earnings of equity method investees, net of taxesNet income attributable to Quest DiagnosticsDiluted EPS
As reported$438 15.9 %$(97)$9 $282 $2.47 
Restructuring and integration charges (a)7 0.3 (2)— 5 0.04 
Other charges (b)28 1.0 (6)— 22 0.19 
Gains and losses on investments (c)— — 1 (1)(2)(0.01)
Other gains (d)(46)(1.7)12 — (34)(0.30)
Amortization expense39 1.4 (11)— 28 0.25 
ETB— — (3)— (3)(0.02)
As adjusted$466 16.9 %$(106)$8 $298 $2.62 
Six Months Ended June 30, 2025
(dollars in millions, except per share data)
Operating incomeOperating income as a percentage of net revenuesIncome tax expense (e)Equity in earnings of equity method investees, net of taxesNet income attributable to Quest DiagnosticsDiluted EPS
As reported$784 14.5 %$(156)$27 $502 $4.41 
Restructuring and integration charges (a)26 0.5 (7)— 19 0.17 
Other charges (b)30 0.6 (6)— 24 0.21 
Gains and losses on investments (c)— — 1 (1)(2)(0.01)
Other gains (d)(46)(0.9)14 (8)(40)(0.36)
Amortization expense78 1.4 (20)— 58 0.51 
ETB— — (12)— (12)(0.10)
As adjusted$872 16.1 %$(186)$18 $549 $4.83 
8


(a)For each of the three and six months ended June 30, 2026 and 2025, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
(dollars in millions)
Cost of services$1 $1 $2 $7 
Selling, general and administrative3 6 9 19 
Operating income$4 $7 $11 $26 

(b)The three and six months ended June 30, 2026 and 2025 include losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions, recorded in other operating expense (income), net. Additionally, for both the three and six months ended June 30, 2025, the pre-tax impact primarily represents a $24 million impairment charge on certain long-lived assets related to the exit of a business, recorded in other operating expense (income), net.

(c)For all periods presented, the pre-tax impact represents gains and losses associated with changes in the carrying value of our strategic investments, principally recorded in equity in earnings of equity method investees, net of taxes, and other income, net.

(d)The three and six months ended June 30, 2025 include a $46 million pre-tax gain, recorded in other operating expense (income), net, from a payroll tax credit under the Coronavirus Aid, Relief, and Economic Security Act associated with the retention of employees. Additionally, the six months ended June 30, 2025 includes an $8 million gain, recorded in equity in earnings of equity method investees, net of taxes, representing a non-recurring gain related to a lease.

(e)For restructuring and integration charges, other gains/charges, gains and losses on investments, and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2026 and 2025. No income tax impact was recorded on losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions.

3)For both the three and six months ended June 30, 2026, we repurchased 0.5 million shares of our common stock for $100 million. As of June 30, 2026, $1.3 billion remained available under our share repurchase authorization.

4)The outlook for adjusted diluted EPS represents management’s estimates for the full year 2026 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2026. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, which are difficult to predict. The following table reconciles our 2026 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS:

LowHigh
Diluted EPS$9.97 $10.17 
Restructuring and integration charges (a)0.14 0.14 
Amortization expense (b)0.99 0.99 
Other charges (c)0.10 0.10 
Gains and losses on investments (d)0.04 0.04 
ETB(0.19)(0.19)
Adjusted diluted EPS$11.05 $11.25 

(a)Represents estimated pre-tax charges of $21 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.

(b)Represents estimated pre-tax amortization expenses of $149 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.

9


(c)Principally represents estimated pre-tax net losses of $9 million associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions. Such estimate is subject to the risks and uncertainties discussed in the "Forward Looking Statements" section above. No income tax benefits are recorded on the changes associated with the contingent consideration accrual.

(d)Income tax impacts were calculated using a combined statutory income tax rate of 25.5%.
10

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents